Top Qs
Timeline
Chat
Perspective
Botaretigene sparoparvovec
Experimental gene therapy From Wikipedia, the free encyclopedia
Remove ads
Botaretigene sparoparvovec (AAV5-RPGR) is an experimental gene therapy for X-linked retinitis pigmentosa developed by Janssen Pharmaceuticals.[1][2]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads